首页> 外文期刊>Vascular pharmacology >Anticoagulant activities of persicarin and isorhamnetin
【24h】

Anticoagulant activities of persicarin and isorhamnetin

机译:波斯卡林和异鼠李素的抗凝活性

获取原文
获取原文并翻译 | 示例
           

摘要

Persicarin and isorhamnetin were isolated from Oenanthe javanica and their anticoagulant activities were examined by monitoring activated partial thromboplastin time (aPTT), prothrombin time (PT), and the activities of cell-based thrombin and activated factor X (FXa). In addition, the effects of persicarin and isorhamnetin on the expressions of plasminogen activator inhibitor type 1 (PAI-1) and tissue-type plasminogen activator (t-PA) were tested in tumor necrosis factor-α (TNF-α) activated human umbilical vein endothelial cells (HUVECs). The data obtained showed that persicarin and isorhamnetin both prolonged aPTT and PT significantly and inhibited the activities of thrombin and FXa. In addition, they both inhibited the generations of thrombin and FXa in HUVECs. In accordance with these anticoagulant activities, persicarin and isorhamnetin prolonged in vivo bleeding time and inhibited TNF-α induced PAI-1 production. Furthermore, PAI-1/t-PA ratio was significantly decreased by persicarin. Interestingly, the anticoagulant and profibrinolytic effects of persicarin were greater than those of isorhamnetin, which suggest that the sulfonate group of persicarin positively regulates its anticoagulatory function. Accordingly, our results suggest that persicarin and isorhamnetin possess antithrombotic activities and that they could provide bases for the development of new anticoagulant agents.
机译:从波斯菊中分离出波斯菊酯和异鼠李素,并通过监测活化的部分凝血活酶时间(aPTT),凝血酶原时间(PT)以及基于细胞的凝血酶和活化因子X(FXa)的活性来检查其抗凝活性。此外,在肿瘤坏死因子-α(TNF-α)活化的人脐带血中测试了persicarin和异鼠李素对纤溶酶原激活物抑制剂1(PAI-1)和组织型纤溶酶原激活物(t-PA)表达的影响。静脉内皮细胞(HUVEC)。获得的数据表明,波斯卡林和异鼠李素均显着延长了aPTT和PT的表达,并抑制了凝血酶和FXa的活性。另外,它们都抑制HUVEC中凝血酶和FXa的产生。根据这些抗凝活性,波斯卡林和异鼠李素可延长体内出血时间并抑制TNF-α诱导的PAI-1产生。此外,波斯卡林可显着降低PAI-1 / t-PA比。有趣的是,Persicarin的抗凝血和纤溶作用比异鼠李素大,这表明Persicarin的磺酸盐基团正调节其抗凝血功能。因此,我们的结果表明,persicarin和isorhamnetin具有抗血栓形成的活性,它们可以为开发新的抗凝剂提供基础。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号